Table 1.

Clinical Characteristics of 36 Cadaveric Renal Transplant Recipients Who Subsequently Developed Invasive CMV Disease

	n(%)
Patient age (y)
Mean	42.1 ± 11.5
Range	18–71
Sex
Male	25 (69)
Female	11 (31)
Panel-reactive antibodies
<4%	20 (56)
4–80%	9 (25)
>80%	7 (19)
Donor age (y)
Median	45
Range	2–67
Donor recipient pretransplant CMV serology
Positive/negative	16 (44)
Positive/positive	9 (25)
Negative/positive	5 (14)
Negative/negative	4 (11)
Treated for acute cellular rejection pre-CMV
Yes	29 (81)
No	7 (19)
Type of treatment for acute cellular rejection
(n = 29)
High-dose steroids	18 (50)
OKT3	2 (6)
Steroids and OKT3	9 (25)